Core Insights - The "Double 11" shopping festival in China has evolved into a prolonged promotional period, with consumers becoming accustomed to discounts and promotions, leading to a decline in consumer enthusiasm [2][6] - Consumer confidence remains low, with the consumer confidence index at 89.6 in September, below the optimistic threshold of 100, indicating ongoing economic challenges [6] - Japanese brands are facing tough competition in the Chinese market, with a notable shift towards domestic products and a slight recovery in sales for certain categories [7][8] E-commerce Trends - E-commerce companies have extended promotional periods to over a month, with JD.com starting promotions three days earlier than in 2024, and Alibaba's promotions lasting until November 14 [6][10] - The trend of "emotional consumption" has emerged, with increased sales in outdoor sports products and cartoon-themed items during the early phase of the Double 11 promotions [6] Japanese Brands in China - Japanese brands are experiencing a decline in circulation on major e-commerce platforms, but there are signs of recovery with a 1% increase in circulation for the first ten months of the year [7] - Specific categories such as sports and outdoor products have seen significant growth, with a 19% increase, while clothing and skincare products grew by 4% [7][8] Consumer Behavior - Consumers are increasingly price-sensitive, with a focus on finding the lowest prices for everyday items, reflecting a shift in purchasing behavior [4][6] - The concept of "fail-proof shopping" is gaining traction among Chinese consumers, emphasizing the need for brands to provide value beyond discounts [10]

天眼查App显示，近日，长沙市丝丝化妆品有限公司成立，法定代表人为黎韬，注册资本20万人民币， 经营范围为一般项目：化妆品零售;卫生用品和一次性使用医疗用品销售;美发饰品销售;互联网销售（除 销售需要许可的商品）;日用百货销售;化妆品批发;日用杂品销售;个人卫生用品销售;化工产品销售（不 含许可类化工产品）;日用化学产品销售;包装材料及制品销售;包装服务;技术进出口;货物进出口;进出口 代理（除依法须经批准的项目外，自主开展法律法规未禁止、未限制的经营活动）。 ...

Core Insights - GROLAND Inc., a wholly-owned subsidiary of Beta Mind, has successfully obtained a cosmetic product listing certificate from Zoop Technical Service, confirming compliance with U.S. FDA regulations for its product "Groland Aqua Kine Scalp Essence" [1] - This achievement signifies that the product meets all legal registration obligations required for market entry in the U.S., enhancing the company's commitment to product quality and safety [1] - The successful registration reflects GROLAND Inc.'s dedication to adhering to U.S. cosmetic regulations, particularly in areas such as ingredient safety, Good Manufacturing Practices (GMP), and labeling compliance [1] Regulatory Achievements - Two active molecules, XTP-118 and XTP-016, have completed the INCI registration process under the oversight of the Personal Care Products Council, allowing for effective tracking of ingredient safety and regulatory status globally [2] - The completion of this registration process indicates that GROLAND Inc.'s products are now qualified for entry into the U.S. market, laying a solid foundation for future brand promotion and global expansion [2]

Core Insights - GROLAND Inc., a wholly-owned subsidiary of Beta Mind, has successfully obtained a cosmetic product listing certificate from Zoop Technical Service, confirming that its product "Groland Aqua Kine Scalp Essence" has completed the registration process with the FDA under the revised MoCRA [1][2] - This achievement signifies compliance with all legal registration obligations required for market entry in the U.S., enhancing the company's commitment to product quality and safety [1] - The successful registration not only demonstrates GROLAND Inc.'s dedication to maintaining high product standards but also strengthens its ability to offer safe and reliable choices to consumers [1] Regulatory Compliance - The product has been registered in accordance with the Federal Food, Drug, and Cosmetic Act, ensuring adherence to U.S. cosmetic regulations, particularly in terms of ingredient safety, Good Manufacturing Practices (GMP), and labeling compliance [1] - The completion of the INCI registration process for two active molecules, XTP-118 and XTP-016, allows for effective tracking of ingredient safety and regulatory status globally, enhancing compliance capabilities [2] Market Positioning - The successful registration marks GROLAND Inc.'s products as qualified for entry into the U.S. market, laying a solid foundation for future brand promotion and global expansion [2]

Core Viewpoint - GROLAND Inc., a wholly-owned subsidiary of BetaMind, has successfully obtained a cosmetic product listing certificate from Zoop Technical Service, marking a significant milestone for the company in entering the U.S. market [1] Group 1: Regulatory Achievements - The certificate confirms that the "Groland Aqua Kine Scalp Essence" complies with the Federal Food, Drug, and Cosmetic Act, as amended by the 2022 Modernization of Cosmetics Regulation Act (MoCRA) [1] - This achievement indicates that the product has met all legal registration obligations required for sale in the U.S. market [1] Group 2: Compliance Commitment - The company is committed to ensuring that all relevant products comply with U.S. cosmetic regulatory requirements, particularly in areas such as ingredient safety, Good Manufacturing Practices (GMP), and labeling compliance [1]

Core Viewpoint - The collagen market is experiencing a downturn, with major brands like Kefu Mei and Juzhi Biotech showing declining sales and growth rates, indicating a shift from a previously booming market to a more cautious phase [1][3][5]. Market Performance - The overall performance of the collagen sector during the 2025 Double Eleven shopping festival was disappointing, with Kefu Mei's GMV on Douyin dropping to 0.5-0.75 billion yuan, down from over 1 billion yuan in the same period last year [3][4]. - Juzhi Biotech's stock price has fallen by 55.18% since reaching a peak of 85.14 HKD on May 20, 2023, reflecting the company's struggles with slowing growth and ingredient controversies [5][6]. Strategic Shifts - Major players are beginning to cross market boundaries, with Juzhi Biotech expanding into B-end business and Kefu Mei attempting to adapt to changing market dynamics [6][7]. - The market is witnessing a transition from a focus on consumer products to medical applications, as companies aim to leverage technological advancements and regulatory clarity [7][10]. Industry Trends - The industry is moving towards a more scientific and clinical approach, with companies like Huaxi Biotech and Furuida actively pursuing medical device certifications and focusing on the development of injectable collagen products [8][9][10]. - The competitive landscape is shifting from brand recognition and channel dominance to a focus on material science and clinical validation, emphasizing the importance of proving product efficacy [10][11].

Core Viewpoint - The stock of Mao Geping (01318) has increased by over 6%, currently up 6.51% at HKD 96.5, with a trading volume of HKD 69.51 million, indicating strong market interest and performance during the recent promotional period [1] Group 1: Sales Performance - The recent Double 11 promotion lasted about a month, concluding around November 11, with Mao Geping showing steady growth across both Douyin and Tmall channels [1] - Tmall's first-day sales featuring Li Jiaqi sold out, reflecting high popularity and consumer demand [1] Group 2: Market Insights - According to Shenwan Hongyuan's report, the competitive landscape during the September Double 11 pre-sale and multi-platform competition has set a solid foundation for Q4 performance [1] - Open Source Securities highlights that domestic brands are leveraging cultural roots to capture "emotional dividends," thereby increasing market share [1] Group 3: Consumer Trends - The report emphasizes the importance of emotional value and safety in product innovation, focusing on opportunities in niche markets such as "regional + technology" narratives, sensitive skin anti-aging, domestic trend cosmetics, and olfactory economy [1]

Group 1 - The stock of Mao Geping (01318) has increased by over 6%, currently up 6.51% at HKD 96.5, with a trading volume of HKD 69.51 million [1] - According to a recent report by Shenwan Hongyuan, the Double 11 promotion in 2025 lasted about a month and concluded around November 11, with expectations of steady growth for Mao Geping on both Douyin and Tmall platforms, as evidenced by the sell-out on the first day of sales with Li Jiaqi on Tmall [1] - The report highlights that Mao Geping's performance in October has laid a solid foundation for Q4 results amidst the backdrop of the September Double 11 pre-sale and multi-platform competition [1] Group 2 - Open Source Securities emphasizes that domestic brands are leveraging cultural foundations to capture "emotional dividends" and increase market share [1] - In the context of evolving consumer mindsets and product innovation, the focus is on two core dimensions: emotional value and safety component innovation, with attention to opportunities in niche markets such as "regional + technology" narrative upgrades, sensitive skin anti-aging, domestic trend cosmetics, and olfactory economy [1]

Group 1 - The company received a significant investment return from its subsidiary's investment in Suzhou Yuanchuang Venture Capital Center, amounting to 3,057,892.45 yuan [2][3] - The investment was made in May 2021, with an initial contribution of 20 million yuan [2] - The received fund distribution will be recorded as investment income in the company's financial statements, impacting the pre-tax profit by 3,057,892.45 yuan, which represents 12.53% of the audited net profit for 2024 [3]

相比之下，曾经叱咤市场的韩妆"老大哥"LG生活健康(韩国首尔证券交易所代码：051900)，从近日(11月10日)发布的最新财报来看，业绩难题开始凸显。 财报显示，2025年前三季度销售额为48827亿韩元(人民币约237.79亿元)，同比下滑6.1%，营业利润为2434亿韩元(人民币约11.85亿元)，同比大幅下滑 41.4%，净利润仅1654亿韩元(人民币约8.04亿元)，同比下降43.7%。 其中，第三季度的销售额下跌7.8%至15800亿韩元(人民币约76.95亿元)，营业利润为462亿韩元(人民币约 2.25亿元)，跌幅扩大至56.5%。财报透露，第三 季度业绩下滑主要因为受到美容(化妆品)业务表现低迷，以及韩国本土需求影响。 图源：LG生活健康官网 随着韩妆几大巨头财报陆续披露，整体韩妆竞争格局开始显现。黑马新秀APR表现尤为抢眼，其营业收入和营业利润保持三位数的强势增长，未来甚至有 望赶超爱茉莉太平洋。 此外，还有以下信息值得关注： 对此，LG生活健康相关人士表示："美容业务的重组是实现新飞跃的重要过程，我们将在新的领导层的带领下努力提高业务竞争力，恢复中长期业绩。" 美容业务单季亏损近3亿元！ ...